Fig. 2

Rag1^−/− mice develop persistent LGGs a Percentage of Rag1^−/− mice harboring LGGs at 1, 3 and 6 mpi. The total number of injected mice is denoted in the parentheses. G, glial only; G/E, mixed glial/embryonal. b Representative H&E staining of NF1-null and KIAA1549:BRAF-expressing LGGs 1, 3 and 6 mpi. The lesions are outlined by the dotted lines. The percentage of the area occupied by the LGG is indicated within each panel. Scale bars, 200 µm. c Representative Ki67 immunohistochemistry images (top panel) and percentages of Ki67⁺ cells in Rag1^−/− mice harboring NF1-null or KIAA1549:BRAF-expressing iNPC glial or mixed/glial embryonal tumors at 1, 3 and 6 mpi. Scale bars, 200 µm d No change in TUNEL⁺ cells (apoptotic cells) in NF1-null and KIAA1549:BRAF-expressing iNPC-derived LGGs were observed 1 (0.41%; 0.38%; 0.38%), 3 (0.36%, 0.37%; 0.34%), and 6 months (0.38%, 0.37%; 0.38%) after injection. Scale bars, 100 µm. Data are represented as means ± SEM, one-way ANOVA with Bonferroni post-test correction, Individual p values are indicated within each graph. ns not significant